| Low risk | PSA < 10 ng/ml Gleason score < 7 Clinical stage T1 – T2a |
| Intermediate risk | PSA 10-20 ng/ml Gleason score 7 Clinical stage T2b |
| High risk | PSA > 20 ng/ml Gleason score > 7 Clinical stage > T2c or N+ |
Risk stratification in prostate cancer by European Association of Urology
